Comparative Effectiveness of Second-Line Agents for the Treatment of Diabetes Type 2 in Preventing Kidney Function Decline | Zendy

Adriana M. Hung | Zendy; Christianne L. Roumie | Zendy; Robert A. Greevy | Zendy; Carlos G. Grijalva | Zendy; Xulei Liu | Zendy; Harvey J. Murff | Zendy; T. Alp İkizler | Zendy; Marie R. Griffin | Zendy

Open Access

Comparative Effectiveness of Second-Line Agents for the Treatment of Diabetes Type 2 in Preventing Kidney Function Decline

Author(s) -

Adriana M. Hung,

Christianne L. Roumie,

Robert A. Greevy,

Carlos G. Grijalva,

Xulei Liu,

Harvey J. Murff,

T. Alp İkizler,

Marie R. Griffin

Publication year - 2016

Publication title -

clinical journal of the american society of nephrology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.755

H-Index - 151

eISSN - 1555-905X

pISSN - 1555-9041

DOI - 10.2215/cjn.02630316

Subject(s) - medicine , interquartile range , hazard ratio , renal function , metformin , type 2 diabetes , retrospective cohort study , propensity score matching , sulfonylurea , proportional hazards model , diabetes mellitus , confidence interval , insulin , endocrinology

Diabetes is the leading cause of ESRD. Glucose control improves kidney outcomes. Most patients eventually require treatment intensification with second-line medications; however, the differential effects of those therapies on kidney function are unknown.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research